Matthew Chandler

VCARD
 

Matthew Chandler, JD

Matthew Chandler, JD, is a Director with over ten years of experience supporting Legal and Compliance departments in the life sciences industry. He regularly assists a wide range of pharmaceutical and medical device companies in a variety of matters, from start-ups developing their initial compliance framework to big pharma clients looking to continuously refine their programs.

He is often retained by clients for interim compliance manager and leadership roles, where he has helped establish the foundation of companies’ compliance programs and led various workstreams. Most recently, in 2025, Matt served as the interim head of compliance for a growing specialty therapeutics company.

Clients also engage him to support in their compliance policy and procedure development, to lead healthcare compliance and enterprise-wide risk assessments, to design and develop live or web-based compliance trainings, and to lead auditing and monitoring activities. He is also a subject matter expert in physician payment transparency laws and works extensively with companies on transparency-related compliance efforts.

Matt also has extensive experience supporting complex and data-intensive investigations and disputes involving the pharmaceutical, medical device, and diagnostic industries. Particular allegations at issue in cases Matt has supported include violations of the Anti-Kickback Statute, False Claims Act, Physician Payments Sunshine Act, Stark Law, and FDA-related regulations. He has also been a member of several Independent Review Organizations (IROs) for companies under CIA and has conducted systems and transactions reviews for numerous activities outlined by the Office of Inspector General (OIG).

Prior to starting his consulting career, Matt was the regulatory analyst and head writer for Policy and Medicine, a prominent life sciences publication with a focus on analyzing government enforcement trends, FDA activity, and transparency requirements. He holds an undergraduate degree from the College of William and Mary and a Juris Doctor from the University of Arizona, where he served as Articles Editor for the Arizona Law Review.


Prosecutor Panel at Compliance Congress for Specialty Products
Prescriptions and Persuasion: Analyzing the Purpose, Risks, and Vulnerabilities of Speaker Programs
How User-Friendly and Effective Are Your Written Standards?
Department of Justice’s September 2024 Update to Evaluation of Corporate Compliance Programs
SIUU Guidance Finalized – What Should We Do?
Highlights from the 20th Annual Pharmaceutical Compliance Congress
Taking Stock of the Recent Flurry of Articles Mining Open Payments Data
Top Ten Takeaways from the 2024 Pharmaceutical Compliance Congress
Top 10 Takeaways from the 25th Annual Pharmaceutical and Medical Device Ethics and Compliance Congress
Top Five Takeaways from the 2025 Pharmaceutical Compliance Congress
 
Dominica Chadafull